Plasma disappearance rate of indocyanine green: a tool to evaluate early graft outcome after liver transplantation.
Indocyanine green clearance (Cl-ICG) has been used to assess liver function and hepatic blood flow mainly before and after hepatic surgery. Cl-ICG (invasive method) has been reported to be a good marker of early graft function after liver transplantation (LT). The goal of this study was to determine if the indocyanine green plasma disappearance rate (PDR-ICG), measured by a noninvasive technique (LiMON, Impulse Medical System, Munich, Germany), is predictive of complications and graft outcome after LT. From September 2005 to June 2006, 72 LT recipients were included in the study. PDR-ICG was measured daily (from day 0 to day 5 after LT) with a digital sensor after patients were injected with 0.25 mg/kg indocyanine green. A PDR-ICG cutoff level of 12.85%/minute was predictive of the development of a serious postoperative complication. The sequential changes of PDR-ICG enabled us to differentiate 2 groups: (1) patients with early severe complications (hepatic artery thrombosis, primary graft nonfunction, or sepsis) who had a low value of PDR-ICG during the first 5 posttransplantation days (average, 8.8 +/- 4.5%/minute) and (2) patients who developed acute rejection and who had a progressive reduction of PDR-ICG between days 0 and 5 (from 25.5 +/- 4.8 to 10.3 +/- 2.5%/minute; P < 0.002). In conclusion, after LT, PDR-ICG (a noninvasive technique), measured regularly during the first 5 postoperative days, is a safe technique that can predict early postoperative complications.
AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
Eric
E
Levesque
Faouzi
F
Saliba
Sonia
S
Benhamida
Philippe
P
Ichaï
Daniel
D
Azoulay
René
R
Adam
Denis
D
Castaing
Didier
D
Samuel
D000328:Adult; D004396:Coloring Agents / Q000493:pharmacokinetics; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007208:Indocyanine Green / Q000493:pharmacokinetics*; D016031:Liver Transplantation / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011184:Postoperative Period; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler / Q000379:methods
D004396:Coloring Agents; D007166:Immunosuppressive Agents; D007208:Indocyanine Green